아세틸콜린에스터레이스 억제제 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "아세틸콜린에스터레이스 억제제" in Korean language version.

refsWebsite

Global rank Korean rank

17nih.gov

4^th place

16doi.org

2^nd place

3^rd place

4semanticscholar.org

11^th place

310^th place

3books.google.com

3^rd place

9^th place

3archive.org

6^th place

18^th place

2web.archive.org

1^st place

1england.nhs.uk

low place

1cochrane.org

7,609^th place

6,795^th place

1consumerreports.org

4,720^th place

3,306^th place

1mayoclinic.com

3,634^th place

1,904^th place

archive.org

Taylor D, Paton C, Shitij K (2012). 《Maudsley Prescribing Guidelines in Psychiatry》 11판. West Sussex: Wiley-Blackwell. ISBN 978-0-47-097948-8.
Karadsheh N, Kussie P, Linthicum DS (March 1991). “Inhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives”. 《Toxicology Letters》 55 (3): 335–42. doi:10.1016/0378-4274(91)90015-X. PMID 2003276.
Rang HP (2003). 《Pharmacology》. Edinburgh: Churchill Livingstone. 156쪽. ISBN 978-0-443-07145-4.

books.google.com

Seth (2009년 11월 18일). 〈23〉. 《Textbook Of Pharmacology》. Elsevier India. III.87쪽. ISBN 978-8131211588. 2019년 6월 18일에 확인함. Anaesthesia: Cholinesterase inhibitors are likely to exaggerate succinylcholine-type muscle relaxation during anaesthesia. 5. Genitourinary system: It may ...
O'Brien, Richard D. (2013년 10월 22일). 《Toxic Phosphorus Esters: Chemistry, Metabolism, and Biological Effects》 (영어). Elsevier. ISBN 978-1-4832-7093-7.
Roberts, Stephen M.; James, Robert C.; Williams, Phillip L. (2014년 12월 8일). 《Principles of Toxicology: Environmental and Industrial Applications》 (영어). John Wiley & Sons. ISBN 978-1-118-98248-8.

cochrane.org

Singh J, Kour K, Jayaram MB (January 2012). “Acetylcholinesterase inhibitors for schizophrenia”. 《The Cochrane Database of Systematic Reviews》 1: CD007967. doi:10.1002/14651858.CD007967.pub2. PMC 6823258. PMID 22258978.
요약본 - Singh J, Kour K, Jayaram MB. “Acetylcholinesterase inhibitors versus antipsychotics for schizophrenia either alone or in combination with antipsychotics”. 《Cochrane》.

consumerreports.org

Consumer Reports; Drug Effectiveness Review Project (May 2012). “Evaluating Prescription Drugs Used to Treat: Alzheimer's Disease Comparing Effectiveness, Safety, and Price” (PDF). 《Best Buy Drugs》: 2. 2012년 9월 5일에 원본 문서 (PDF)에서 보존된 문서. 2013년 5월 1일에 확인함. , which claims Alzheimer's Association guidance as a source

doi.org

dx.doi.org

English, Brett A.; Webster, Andrew A. (2012). 〈Acetylcholinesterase and its Inhibitors〉. 《Primer on the Autonomic Nervous System》. Elsevier. 631–633쪽. doi:10.1016/b978-0-12-386525-0.00132-3. ISBN 978-0-12-386525-0.
Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM (May 2013). “Acetylcholinesterase inhibitors: pharmacology and toxicology”. 《Current Neuropharmacology》 (Bentham Science Publishers Ltd.) 11 (3): 315–35. doi:10.2174/1570159x11311030006. PMC 3648782. PMID 24179466.
McGleenon BM, Dynan KB, Passmore AP (October 1999). “Acetylcholinesterase inhibitors in Alzheimer's disease”. 《British Journal of Clinical Pharmacology》 48 (4): 471–80. doi:10.1046/j.1365-2125.1999.00026.x. PMC 2014378. PMID 10583015.
Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM (May 2013). “Acetylcholinesterase inhibitors: pharmacology and toxicology”. 《Current Neuropharmacology》 11 (3): 315–35. doi:10.2174/1570159X11311030006. PMC 3648782. PMID 24179466.
Lotti M, Moretto A (2005년 1월 1일). “Organophosphate-induced delayed polyneuropathy”. 《Toxicological Reviews》 24 (1): 37–49. doi:10.2165/00139709-200524010-00003. PMID 16042503. S2CID 29313644.
Singh J, Kour K, Jayaram MB (January 2012). “Acetylcholinesterase inhibitors for schizophrenia”. 《The Cochrane Database of Systematic Reviews》 1: CD007967. doi:10.1002/14651858.CD007967.pub2. PMC 6823258. PMID 22258978.
요약본 - Singh J, Kour K, Jayaram MB. “Acetylcholinesterase inhibitors versus antipsychotics for schizophrenia either alone or in combination with antipsychotics”. 《Cochrane》.
Choi KH, Wykes T, Kurtz MM (September 2013). “Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy”. 《The British Journal of Psychiatry》 203 (3): 172–8. doi:10.1192/bjp.bp.111.107359. PMC 3759029. PMID 23999481.
Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM (April 2010). “Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature”. 《CNS Drugs》 24 (4): 303–17. doi:10.2165/11530260-000000000-00000. PMID 20297855. S2CID 45807136.
Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, Thurm A, Sato S, Swedo S (August 2011). “An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders”. 《Journal of Child and Adolescent Psychopharmacology》 21 (4): 353–7. doi:10.1089/cap.2010.0121. PMC 3157749. PMID 21851192.
Handen BL, Johnson CR, McAuliffe-Bellin S, Murray PJ, Hardan AY (February 2011). “Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures”. 《Journal of Child and Adolescent Psychopharmacology》 21 (1): 43–50. doi:10.1089/cap.2010.0024. PMC 3037196. PMID 21309696.
Karadsheh N, Kussie P, Linthicum DS (March 1991). “Inhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives”. 《Toxicology Letters》 55 (3): 335–42. doi:10.1016/0378-4274(91)90015-X. PMID 2003276.
Vladimir-Knežević S, Blažeković B, Kindl M, Vladić J, Lower-Nedza AD, Brantner AH (January 2014). “Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family”. 《Molecules》 19 (1): 767–82. doi:10.3390/molecules19010767. PMC 6271370. PMID 24413832.
Miyazawa M, Yamafuji C (March 2005). “Inhibition of acetylcholinesterase activity by bicyclic monoterpenoids”. 《Journal of Agricultural and Food Chemistry》 53 (5): 1765–8. doi:10.1021/jf040019b. PMID 15740071.
Perry NS, Houghton PJ, Theobald A, Jenner P, Perry EK (July 2000). “In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes”. 《The Journal of Pharmacy and Pharmacology》 52 (7): 895–902. doi:10.1211/0022357001774598. PMID 10933142. S2CID 34457692.
Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ (April 2009). “Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis”. 《Journal of Neural Transmission》 116 (4): 457–65. doi:10.1007/s00702-009-0189-x. PMID 19221692. S2CID 8655284.
Rhee IK, Appels N, Hofte B, Karabatak B, Erkelens C, Stark LM, Flippin LA, Verpoorte R (November 2004). “Isolation of the acetylcholinesterase inhibitor ungeremine from Nerine bowdenii by preparative HPLC coupled on-line to a flow assay system”. 《Biological & Pharmaceutical Bulletin》 27 (11): 1804–9. doi:10.1248/bpb.27.1804. PMID 15516727.

england.nhs.uk

“Medications for treating people with dementia” (PDF). 2021년 1월 1일에 확인함.

mayoclinic.com

Bauer, Brent A. “Huperzine A: Can it treat Alzheimer's?”. 《Mayo Clinic》. 2012년 8월 19일에 원본 문서에서 보존된 문서.

nih.gov

ncbi.nlm.nih.gov

Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM (May 2013). “Acetylcholinesterase inhibitors: pharmacology and toxicology”. 《Current Neuropharmacology》 (Bentham Science Publishers Ltd.) 11 (3): 315–35. doi:10.2174/1570159x11311030006. PMC 3648782. PMID 24179466.
McGleenon BM, Dynan KB, Passmore AP (October 1999). “Acetylcholinesterase inhibitors in Alzheimer's disease”. 《British Journal of Clinical Pharmacology》 48 (4): 471–80. doi:10.1046/j.1365-2125.1999.00026.x. PMC 2014378. PMID 10583015.
Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM (May 2013). “Acetylcholinesterase inhibitors: pharmacology and toxicology”. 《Current Neuropharmacology》 11 (3): 315–35. doi:10.2174/1570159X11311030006. PMC 3648782. PMID 24179466.
Lotti M, Moretto A (2005년 1월 1일). “Organophosphate-induced delayed polyneuropathy”. 《Toxicological Reviews》 24 (1): 37–49. doi:10.2165/00139709-200524010-00003. PMID 16042503. S2CID 29313644.
Singh J, Kour K, Jayaram MB (January 2012). “Acetylcholinesterase inhibitors for schizophrenia”. 《The Cochrane Database of Systematic Reviews》 1: CD007967. doi:10.1002/14651858.CD007967.pub2. PMC 6823258. PMID 22258978.
요약본 - Singh J, Kour K, Jayaram MB. “Acetylcholinesterase inhibitors versus antipsychotics for schizophrenia either alone or in combination with antipsychotics”. 《Cochrane》.
Choi KH, Wykes T, Kurtz MM (September 2013). “Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy”. 《The British Journal of Psychiatry》 203 (3): 172–8. doi:10.1192/bjp.bp.111.107359. PMC 3759029. PMID 23999481.
Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM (April 2010). “Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature”. 《CNS Drugs》 24 (4): 303–17. doi:10.2165/11530260-000000000-00000. PMID 20297855. S2CID 45807136.
Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, Thurm A, Sato S, Swedo S (August 2011). “An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders”. 《Journal of Child and Adolescent Psychopharmacology》 21 (4): 353–7. doi:10.1089/cap.2010.0121. PMC 3157749. PMID 21851192.
Handen BL, Johnson CR, McAuliffe-Bellin S, Murray PJ, Hardan AY (February 2011). “Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures”. 《Journal of Child and Adolescent Psychopharmacology》 21 (1): 43–50. doi:10.1089/cap.2010.0024. PMC 3037196. PMID 21309696.
Inglis F (June 2002). “The tolerability and safety of cholinesterase inhibitors in the treatment of dementia”. 《International Journal of Clinical Practice. Supplement》 (127): 45–63. PMID 12139367.
Singh, Ravneet; Sadiq, Nazia M. (2020), “Cholinesterase Inhibitors”, 《StatPearls》 (Treasure Island (FL): StatPearls Publishing), PMID 31335056, 2020년 10월 12일에 확인함
Karadsheh N, Kussie P, Linthicum DS (March 1991). “Inhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives”. 《Toxicology Letters》 55 (3): 335–42. doi:10.1016/0378-4274(91)90015-X. PMID 2003276.
Vladimir-Knežević S, Blažeković B, Kindl M, Vladić J, Lower-Nedza AD, Brantner AH (January 2014). “Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family”. 《Molecules》 19 (1): 767–82. doi:10.3390/molecules19010767. PMC 6271370. PMID 24413832.
Miyazawa M, Yamafuji C (March 2005). “Inhibition of acetylcholinesterase activity by bicyclic monoterpenoids”. 《Journal of Agricultural and Food Chemistry》 53 (5): 1765–8. doi:10.1021/jf040019b. PMID 15740071.
Perry NS, Houghton PJ, Theobald A, Jenner P, Perry EK (July 2000). “In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes”. 《The Journal of Pharmacy and Pharmacology》 52 (7): 895–902. doi:10.1211/0022357001774598. PMID 10933142. S2CID 34457692.
Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ (April 2009). “Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis”. 《Journal of Neural Transmission》 116 (4): 457–65. doi:10.1007/s00702-009-0189-x. PMID 19221692. S2CID 8655284.
Rhee IK, Appels N, Hofte B, Karabatak B, Erkelens C, Stark LM, Flippin LA, Verpoorte R (November 2004). “Isolation of the acetylcholinesterase inhibitor ungeremine from Nerine bowdenii by preparative HPLC coupled on-line to a flow assay system”. 《Biological & Pharmaceutical Bulletin》 27 (11): 1804–9. doi:10.1248/bpb.27.1804. PMID 15516727.

semanticscholar.org

api.semanticscholar.org

Lotti M, Moretto A (2005년 1월 1일). “Organophosphate-induced delayed polyneuropathy”. 《Toxicological Reviews》 24 (1): 37–49. doi:10.2165/00139709-200524010-00003. PMID 16042503. S2CID 29313644.
Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM (April 2010). “Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature”. 《CNS Drugs》 24 (4): 303–17. doi:10.2165/11530260-000000000-00000. PMID 20297855. S2CID 45807136.
Perry NS, Houghton PJ, Theobald A, Jenner P, Perry EK (July 2000). “In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes”. 《The Journal of Pharmacy and Pharmacology》 52 (7): 895–902. doi:10.1211/0022357001774598. PMID 10933142. S2CID 34457692.
Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ (April 2009). “Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis”. 《Journal of Neural Transmission》 116 (4): 457–65. doi:10.1007/s00702-009-0189-x. PMID 19221692. S2CID 8655284.

web.archive.org

Consumer Reports; Drug Effectiveness Review Project (May 2012). “Evaluating Prescription Drugs Used to Treat: Alzheimer's Disease Comparing Effectiveness, Safety, and Price” (PDF). 《Best Buy Drugs》: 2. 2012년 9월 5일에 원본 문서 (PDF)에서 보존된 문서. 2013년 5월 1일에 확인함. , which claims Alzheimer's Association guidance as a source
Bauer, Brent A. “Huperzine A: Can it treat Alzheimer's?”. 《Mayo Clinic》. 2012년 8월 19일에 원본 문서에서 보존된 문서.